Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics
- PMID: 17455324
- DOI: 10.1002/jps.20916
Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics
Abstract
The performance of dry powder aerosols for the delivery of drugs to the lungs has been studied extensively in the last decade. The focus for different research groups has been on aspects of the powder formulation, which relate to solid state, surface and interfacial chemistry, bulk properties (static and dynamic) and measures of performance. The nature of studies in this field, tend to be complex and correlations between specific properties and performance seem to be rare. Consequently, the adoption of formulation approaches that on a predictive basis lead to desirable performance has been an elusive goal but one that many agree is worth striving towards. The purpose of this paper is to initiate a discussion of the use of a variety of techniques to elucidate dry particle behavior that might guide the data collection process. If the many researchers in this field can agree on this, or an alternative, guide then a database can be constructed that would allow predictive models to be developed. This is the first of two papers that discuss static and dynamic methods of characterizing dry powder inhaler formulations.
(c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
Similar articles
-
Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics.J Pharm Sci. 2007 May;96(5):1302-19. doi: 10.1002/jps.20943. J Pharm Sci. 2007. PMID: 17455364
-
Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.J Aerosol Med Pulm Drug Deliv. 2015 Aug;28(4):254-67. doi: 10.1089/jamp.2014.1146. Epub 2014 Dec 17. J Aerosol Med Pulm Drug Deliv. 2015. PMID: 25517187
-
Lactose composite carriers for respiratory delivery.Pharm Res. 2009 Apr;26(4):802-10. doi: 10.1007/s11095-008-9779-9. Epub 2008 Nov 18. Pharm Res. 2009. PMID: 19015956
-
Dry powder aerosol delivery systems: current and future research directions.J Aerosol Med. 2006 Spring;19(1):21-7. doi: 10.1089/jam.2006.19.21. J Aerosol Med. 2006. PMID: 16551211 Review.
-
Development of dry powder inhalers.Recent Pat Drug Deliv Formul. 2007;1(1):11-21. doi: 10.2174/187221107779814159. Recent Pat Drug Deliv Formul. 2007. PMID: 19075871 Review.
Cited by
-
Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.AAPS J. 2015 Sep;17(5):1105-16. doi: 10.1208/s12248-015-9775-z. Epub 2015 May 9. AAPS J. 2015. PMID: 25956383 Free PMC article.
-
Phase transited asymmetric membrane floating nanoparticles: a means for better management of poorly water-soluble drugs.Daru. 2021 Dec;29(2):241-253. doi: 10.1007/s40199-020-00382-5. Epub 2021 Aug 20. Daru. 2021. PMID: 34417727 Free PMC article.
-
Process optimization and particle engineering of micronized drug powders via milling.Drug Deliv Transl Res. 2018 Dec;8(6):1740-1750. doi: 10.1007/s13346-017-0444-x. Drug Deliv Transl Res. 2018. PMID: 29134556 Review.
-
Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.AAPS J. 2020 Nov 16;23(1):2. doi: 10.1208/s12248-020-00531-3. AAPS J. 2020. PMID: 33200330 Free PMC article.
-
Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery.Pharmaceutics. 2021 Dec 17;13(12):2188. doi: 10.3390/pharmaceutics13122188. Pharmaceutics. 2021. PMID: 34959469 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources